MedTrace Logo

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

NCT01615068 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1007

Last updated 2018-07-16

No results posted yet for this study

Summary

This multi-center, prospective observational study will evaluate the treatment patterns, and the safety in patients with HER2-positive (HER2+) metastatic breast cancer (MBC). Eligible patients will have an initial metastatic breast cancer diagnosis that has not been previously treated with systemic therapy; patients may be enrolled up to 6 months after the diagnosis. Data will be collected for up to 8 years.

Conditions

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Genentech, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-05
Primary Completion
2017-11-16
Completion
2017-11-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01615068 on ClinicalTrials.gov